BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37158302)

  • 1. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.
    Serra A; Mozgunov P; Jaki T
    Stat Med; 2023 Jul; 42(16):2841-2854. PubMed ID: 37158302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An order restricted multi-arm multi-stage clinical trial design.
    Serra A; Mozgunov P; Jaki T
    Stat Med; 2022 Apr; 41(9):1613-1626. PubMed ID: 35048391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
    Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
    BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
    Bassi A; Berkhof J; de Jong D; van de Ven PM
    Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive power.
    Liu Q; Hu G; Ye B; Wang S; Wu Y
    Pharm Stat; 2023 Mar; 22(2):349-364. PubMed ID: 36418025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
    Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
    Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully order restricted multi-arm multi-stage clinical trial design.
    Kanapka L; Ivanova A
    Stat Med; 2023 Jul; 42(17):3050-3066. PubMed ID: 37190881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
    Yu Z; Ramakrishnan V; Meinzer C
    J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled multi-arm platform design using predictive probability.
    Hobbs BP; Chen N; Lee JJ
    Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.